Clinical Trial Search

Primary: Number of Participants Assessed for Intensive (110-140 mm Hg) and Standard (155-165mm Hg) Pre-dialysis Standardized BP Goal — 62; 64 participants

Primary: The Change of Blood Pressure — -22.7; -5 mmHg

Primary: Renal Oxygenation Changes After Chronic Treatment With Aliskiren or Hydrochlorothiazide — 20.5; 19.5; 19.5; 20.5 1/sec

Primary: Percentage of Participants With Reported Adverse Events (Total Adverse Events, Serious Adverse Events and Death) — 31.3; 0; 27.8; 43.8 Percentage of participants

Primary: Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period — -1.5; -3.7; -0.4 mm Hg

Primary: Office Systolic Blood Pressure Reduction — -31.7; 0.9 mmHg

Primary: Adverse Events — 47.8 percentage of participants

Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) — -28.82; -26.22 mmHg

Primary: Composite Endpoint: Death From Cardiovascular or Renal Causes, Stroke, Myocardial Infarction, Hospitalization for CHF, Progressive Renal Insufficiency, or Permanent…

Primary: Cardiac Output — 3.9; 4.10; 4.6 L/min

Primary: Change in Office Systolic BP — -31.1 mmHg — p=<0.0001

Primary: Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8) — -31.37; -27.99; -30.77; -37.92 mmHg

Primary: Changes in Left Ventricular Mass Index — -1; -9; -6; -14 g/m^2

Primary: Change in Lateral Mitral Annular Myocardial Relaxation Velocity — 1.544; 1.476 cm/s

Primary: Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (MASBP) at Week 8 — -15.3; -11.5 mmHg

Primary: Systolic Blood Pressure — 155.8; 154.3; 155.7; 150.4 mmHg

Primary: Change in Resting Muscle Sympathetic Nerve Activity (MSNA) — -7.5; 3.2 bursts/minute

Primary: Change From Baseline to 12 Weeks in Systolic Ambulatory Blood Pressure in the Chlorthalidone Group Compared to Placebo. — -11.0; -0.5 mm Hg

Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8 — 167.08; 167.41; 130.73; 137.87 mmHg

Primary: Change From Baseline to Week 8 in Mean Sitting Systolic Blood Pressure (msSBP) — -30.38; -20.15 mm Hg

Primary: Percentage of Participants (Defined as Estimated Cumulative Control Rate) Reaching Blood Pressure Target in a Stepped Care, Aliskiren-based Regimen — 86.12 Percentage of…

Primary: Acute and Chronic Safety by Evaluating Incidence of Major Adverse Events — 204; 130; 2; 1 Participants

Primary: Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the Study — -3.12 mmHg

Primary: Number of Participants Remaining on Spironolactone at Week 12 — 126; 98 Participants — p=<0.0001

Primary: Change in Systolic and Diastolic Blood Pressure at Six (6) Months as Measured by Office-based Blood Pressure Assessment — -24.5; -10.3 mm Hg

Primary: Change of Systolic Ambulatory Blood Pressure From Baseline to 12 Weeks — -10.5 mmHg — p=0.01

Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) — 167.0; 168.2; 138.9; 151.6 mm Hg

Primary: Proportion of Subjects in Each Arm That Experience Safety Composite Events — 1; 3 Participants — p=0.28

Primary: Number of Group Counseling Sessions Attended by Participants Randomized to the Treatment Arm — 8.9 sessions per participant

Primary: Incidence of Major Adverse Events That Occurred Within 30 Days Post-procedure. — 0.0 percentage of participants